Last reviewed · How we verify
Kaposi's Sarcoma Skin Lesions — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Panretin | ALITRETINOIN | Advanz | Retinoid [EPC] | Retinoic acid receptor beta | 1999-01-01 | |
| Retin-A | TRETINOIN | Bausch Health | Retinoid [EPC] | Nuclear receptor ROR-beta | 1971-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
- — Retin-A · FDA · approved · US
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Advanz · 1 drug in Kaposi's Sarcoma Skin Lesions
- Bausch Health · 1 drug in Kaposi's Sarcoma Skin Lesions
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Kaposi's Sarcoma Skin Lesions:
- Kaposi's Sarcoma Skin Lesions treatment updates — RSS
- Kaposi's Sarcoma Skin Lesions treatment updates — Atom
- Kaposi's Sarcoma Skin Lesions treatment updates — JSON
Cite this brief
Drug Landscape (2026). Kaposi's Sarcoma Skin Lesions — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/kaposi-s-sarcoma-skin-lesions. Accessed 2026-06-10.
Related
- Kaposi's Sarcoma Skin Lesions full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing